Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer

Published:2008-01-01 Issue:S1 Volume:13 Page:14-20
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

de Marinis Filippo¹,Grossi Francesco²

Affiliation:

1. a Thoracic Oncology Unit I, Department of Lung Diseases, San Camillo and Forlanini Hospitals, Rome, Italy

2. b Medical Oncology A, Disease Management Team – Lung Cancer, National Institute for Cancer Research, Genova, Italy

Abstract

Abstract In the U.S. and Europe, the current options for the second- and third-line treatment of advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents. Docetaxel was the first drug approved for second-line treatment after two phase III trials demonstrated its superiority over best supportive care (BSC) alone and single-agent chemotherapy. Pemetrexed was also registered for use as second-line therapy after it was demonstrated to have activity comparable with, and a more favorable toxicity profile than, docetaxel. Erlotinib, an epidermal growth factor receptor inhibitor, is the only biological agent to have been approved in the U.S. and Europe for lung cancer treatment after a study showed its superiority over BSC in recurrent (second-/third-line) NSCLC patients. This review focuses on these drugs, dealing with the results supporting the choice among docetaxel, pemetrexed, and erlotinib in second- and/or third-line treatment.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.13-S1-14

Reference35 articles.

1. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003;Pfister;J Clin Oncol,2004

2. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

3. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group;Fossella;J Clin Oncol,2000

4. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial;Dancey;Lung Cancer,2004

5. Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer;Quoix;Ann Oncol,2004

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capmatinib inMETExon 14–Mutated orMET-Amplified Non–Small-Cell Lung Cancer;New England Journal of Medicine;2020-09-03

2. The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer;Expert Opinion on Pharmacotherapy;2018-10-24

3. In silico identification and in vitro validation of nogalamycin N ‐oxide (NSC116555) as a potent anticancer compound against non–small‐cell lung cancer cells;Journal of Cellular Biochemistry;2018-10-15

4. MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process;Molecules and Cells;2017

5. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis;Drug Design, Development and Therapy;2015-07